---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-013204"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:22:18.226261+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InMed Q2 net loss $2.6M, cash burn continues; BayMedica profitable amid revenue drop

## Summary
- Q2 net loss $2.6M vs $1.5M YoY; BayMedica revenue $1.1M (-10% YoY).
- Cash $3.5M at Dec 31, 2024; raised $2.9M in Jan 2025; expects funding through Q2 2025.
- INM-901 Alzheimer's preclinical data reduced neuroinflammatory markers; INM-089 IVT formulation for dry AMD.
- Director Janet Grove resigned after withheld votes at Dec 2024 AGM; board to find replacement.
- BayMedica net income $0.23M (+189%) despite revenue drop due to cost cuts.

## SEC filing metadata
- accession: 0001213900-25-013204
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025013204/0001213900-25-013204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025013204/ea0230951-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-013204
- JSON: https://secwatch.observer/filing/0001213900-25-013204.json
- Plain text: https://secwatch.observer/filing/0001213900-25-013204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.